Financials

Financials — What the Numbers Say

Figures converted from Indian rupees at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

GSFC reports in Indian rupees; this page restates the same figures in US dollars. All currency amounts are in US dollar millions ($M) unless stated otherwise. Fiscal year ends 31 March (FY2025 = year ended 31 March 2025).

Financials in One Page

GSFC is a mid-size, integrated Indian fertilizer-and-chemicals PSU running at roughly $116M of trailing-twelve-month revenue, with two distinct earnings layers: a price-controlled fertilizer business that earns thin, subsidy-dependent margins and an industrial chemicals book (caprolactam/nylon-6, melamine, methanol) that swings the P&L through the cycle. Reported revenue grew from $90M in FY2014 to a $138M peak in FY2023, then fell back to $112M in FY2025; operating margin tracked the same arc — 9–11% normal, 14–15% at the FY2022–23 caprolactam peak, 6–7% in the FY2024–25 reset. The headline P&L looks acceptable, but earnings have not converted to cash for two straight years — FY2024 free cash flow was negative $6.1M against a $6.8M profit, and FY2025 was negative $3.5M against $6.9M — because subsidy receivables, inventory, and capex have moved against the company. The balance sheet is the saving grace: borrowings are effectively zero ($0.02M), investments are $59M (~72% of market cap), and the stock trades at 0.58x book and 10x trailing earnings — cheap on the surface, but the discount reflects single-digit ROCE/ROE and PSU control. The single financial metric that matters next is operating cash flow — until CFO normalises, the cheap multiple is not actually cheap.

How to read this page: Section 2 covers what drives the income statement. Section 3 tests whether those earnings are real cash. Section 4 examines balance-sheet flexibility. Section 5 explains capital allocation. Section 6 (segment) is constrained by data limits. Section 7 builds the valuation case. Section 8 compares with peers. Section 9 is the watchlist.

---

2. Revenue, Margins, and Earnings Power

GSFC's earnings power is cyclical, not compounding. Revenue rose from $90M in FY2014 to $112M in FY2025, but reported net income peaked twice ($7.3M in FY2018, $15.4M in FY2023) and round-tripped both times. The single biggest swing factor is the caprolactam–nylon-6 spread (the gap between benzene/ammonia inputs and finished caprolactam prices) — that is what drove the FY2022–23 spike in operating margin from a 9% normal to 15%, and it is what collapsed margins back to 6–7% when global polymer demand cooled.

The shape of this chart is the whole story. Revenue trends gently upward; operating profit and net income are spiky. A multi-year average is more informative than any single year: 12-year mean revenue is $104.5M, mean operating profit $9.9M (9.5% margin), mean net income $7.3M. Trailing-twelve-month numbers (revenue ~$117M, operating profit ~$9.0M, net income ~$7.9M) sit above the long-run average, which is one reason the market treats reported earnings as "above mid-cycle."

The margin story is the chemicals story

Operating margin = profit from sale of goods, before interest, depreciation, tax and other income. It strips out one-off items and shows core profitability per dollar of revenue.

Two patterns matter. First, net margin holds up better than operating margin in down-cycles because GSFC's investment book throws off ~$1–5M of "other income" (interest, dividends, MTM) every year — in FY2020 that other income line ($1.4M) was 75% of net income. Second, the mid-cycle operating margin is 9–11%, not 14–15%. Underwriting GSFC at FY2022–23 margins is the most common analytical mistake.

Recent trajectory: stalled, not broken

Revenue has bottomed and is climbing — Q2 FY2026 hit $35.9M, the highest non-Q3 revenue in the dataset and ~14% above the year-ago quarter (US dollar terms; rupee growth was wider because the rupee weakened). Operating profit followed ($3.8M in Q2 FY2026 vs $3.4M a year prior). Trailing-twelve-month operating profit of ~$9.0M is recovering toward the long-run average but is well below the FY2023 peak of $19.3M. The earnings inflection is real but modest. The fertilizer season (Q2: kharif, Q3: rabi) drives the seasonality: Q1 and Q4 are structurally weak.

---

3. Cash Flow and Earnings Quality

This is where the GSFC investment thesis is decided.

Free cash flow (FCF) is the cash a business generates after covering operating needs (working capital) and capital expenditures. If FCF persistently lags net income, reported earnings are not really turning into shareholder cash.

The 12-year cumulative numbers tell the truth. Cumulative net income FY2014–FY2025: $88.1M. Cumulative free cash flow: $48.7M. Cash conversion is roughly 55% — for every dollar of reported profit over the cycle, only ~55 cents turned into deployable cash. The shortfall went into working capital (mostly fertilizer-subsidy receivables that the Indian government settles with a lag) and into a step-up in capex.

Why FCF is negative in FY2024–25

Three things are happening simultaneously:

1. Cash from operations collapsed from $11.2M (FY2023) to negative $3.2M (FY2024) and recovered only to $1.0M (FY2025). The bulk of the swing is working-capital absorption — inventory days rose from 70 to 89 over two years, and receivables timing has been choppy.
2. Capex stepped up. Capital expenditure averaged $3–5M historically; in FY2024–25 it was higher (CWIP — capital work-in-progress — rose from $2.4M to $8.1M at FY25 close, signalling a project pipeline being built up).
3. Other income subsidised reported profit. Other income hit $4.6M in FY2024 and $3.8M in FY2025, ~50% of pretax profit. Strip it out and core operating profit / capex coverage looks much weaker.

FCF margin has been negative in 5 of 12 years. There is no consistent cash machine here — there is a business that occasionally throws off $20–24M of cash (FY2014, FY2021) when working capital releases, and a business that occasionally absorbs $3–7M (FY2016, FY2018, FY2020, FY2024, FY2025). The 12-year average FCF margin is 4.5%.

Cash-flow distortion table

---

4. Balance Sheet and Financial Resilience

If the cash-flow story is the bear case, the balance sheet is the bull case.

Three points stand out:

1. The deleveraging in FY2021 was decisive. Borrowings dropped from $20.6M (FY2020) to $0.5M (FY2021) — likely a one-time settlement using the fertilizer-subsidy back-payment that the Government of India released that year. Borrowings have stayed essentially zero ($0.02M at FY2025 close).
2. The investment book is huge. $59.1M at FY2025 close is 72% of the current ~$74M market cap (at the current FX rate). A meaningful share is cross-holdings in other Gujarat State PSUs (notably GNFC), so it is not all "deployable cash" — but interest, dividend, and MTM income from this book is what holds up reported net income.
3. Equity book has compounded from $70.5M (FY2014) to $142.0M (FY2025) — the growth is partly real compounding and partly affected by FX (rupee depreciation against USD reduces the dollar carrying value). In rupees the CAGR is ~9.6%; in dollars it is ~6.6%. Per-share book value is $3.21 (40 Cr shares × ₹2 face translated at the current rate). The stock at $1.86 trades at 0.58× book.

Liquidity & resilience scorecard

Interest coverage = EBIT / interest expense. Anything above 4× is investment-grade comfortable; above 10× is essentially unleveraged. GSFC sits near 80×, which is what you would expect from a debt-free balance sheet.

Working capital tells a more nuanced story than the headline. Debtor days collapsed from a peak of 197 (FY2016) to ~20 (FY2022 onwards) — the subsidy mechanism is much faster now than it was before the Direct Benefit Transfer (DBT) regime. But total working-capital days have crept back up from 84 (FY2024) to 93 (FY2025), with inventory days rising to 89 — the visible cause of the FY2025 cash drag. Watch this in the next four quarters: a return toward 80–85 days would release $18–30M of cash.

---

5. Returns, Reinvestment, and Capital Allocation

If you only look at one chart in this section, look at this one.

ROCE (Return on Capital Employed) = EBIT / (debt + equity). It measures pre-tax operating return on every dollar of capital the business uses. India's risk-free rate sits around 7%; 12–15% is industry-average for Indian chemicals; 20%+ is best-in-class.

GSFC's mid-cycle ROCE is 8–9% — barely above the Indian risk-free rate. The peaks (FY2022–23 at 13%) were genuine cycle highs. The current 6% is a cycle trough. This is the key reason the stock trades below book value. Coromandel and Chambal earn 22–27% ROCE; Paradeep earns 14%. GSFC sits at the bottom of the peer group.

Capital allocation: dividend-only, no buyback, no dilution

Capital allocation is mechanical: pay out 20–35% of reported earnings as dividend (with a 50% kicker in the FY2023 peak year), no buybacks, no equity issuance. Equity capital has been frozen at ~$0.94M (40 Cr shares × ₹2 face) for the entire 12-year period. Per-share book value has therefore tracked retained earnings — about $1.76 (FY2014) to $3.55 (FY2025), a ~6.6% CAGR in dollar terms.

What management is not doing is also telling. With $53M+ of net cash + investments — 72% of market cap — and the stock at 0.58× book, a value-maximising private operator would be running a tender offer at, say, $2.30 to retire 10% of float at a discount. That GSFC does not do this is the PSU governance signal — capital is owned by the Gujarat State and tactically immobile. The investment book is functionally permanent.

Book value compounds; EPS is volatile; FCF per share is the worst of the three. Cumulative FCF per share over the 12-year period is ~$1.20 — versus ~$1.79 of book-value growth and ~$2.21 of cumulative EPS. The "missing" value sits in the investment portfolio and the working-capital build, not in the operating business.

---

6. Segment and Unit Economics

GSFC reports two segments — Fertilizers and Industrial Products — but a clean machine-readable segmentation series was not available in this run's data set; the segment file came back unpopulated. Based on company disclosures, the FY2024–25 mix is approximately 60–65% fertilizers / 35–40% industrial products by revenue, but operating profit mix is much more skewed toward industrial products in upcycles (caprolactam–nylon-6 was responsible for the FY2022–23 margin spike). Fertilizers earn a regulated, low-teens-of-EBIT-margin spread; industrial products swing from low single-digit margins in trough years to mid-20% margins at the peak.

The investor takeaway without segment data is to treat the caprolactam–nylon spread and benzene/ammonia input costs as the single most important external variable for GSFC's margin direction. Fertilizer volumes are stable; industrial chemicals are the lever.

Note: a refresh of the segment data set (or segment narrative pulled from the FY2025 annual report) is the first thing to add to this page on the next iteration.

---

7. Valuation and Market Expectations

The reader needs to hold three numbers in mind: $1.86 share price, $3.21 book value per share, $0.20 trailing EPS.

P/B (Price-to-Book) = market cap / shareholders' equity. Below 1× usually means the market expects future returns on equity to fall short of the cost of equity. EV/EBITDA = (market cap + debt − cash) / EBITDA, a leverage-neutral way to compare cash earning power to enterprise value.

The cleanest valuation lens is enterprise value stripped of the investment book:

• Market cap $74.2M
• Plus borrowings $0.02M
• Minus investments $53.5M (treating the cross-holdings + financial portfolio as a separable asset)
• = Ex-cash EV ≈ $20.7M

Against TTM EBITDA of ~$11.2M (operating profit ~$9.0M + depreciation ~$2.2M), that is EV/EBITDA of ~2.0× on the operating business, while the headline market-cap-to-EBITDA on the consolidated entity is ~7.1×. Either way, GSFC trades at a structural discount to fertilizer/chemicals peers (Coromandel ~17× P/EBITDA, Chambal ~7×, Paradeep ~9×).

The 10-year P/E range has been 4.5–23×. The current 10× is roughly mid-band. Importantly, the FY2023 trough of 4.5× was at peak earnings (the market was pricing a normalisation, correctly). The current 10× sits on slightly-below-mid-cycle earnings, so it is not as cheap as it looks.

Bear / base / bull triangulation

The valuation argument is asymmetric only if the business returns to mid-cycle. Today's 10× P/E with single-digit ROCE and negative FCF does not imply skewed upside on its own. The thesis depends on either (a) chemical-cycle margin recovery, or (b) capital-allocation reform (special dividend, monetisation of cross-holdings), or (c) both.

---

8. Peer Financial Comparison

The cleanest way to read this table is to look at columns 4 and 7: ROCE and P/B. They tell you what the market is pricing.

The peer set splits into three buckets:

• Quality compounders (Coromandel, Chambal): 22–27% ROCE, 17–20% ROE, trading at 1.9–4.5× book. Their margins are wider, asset turns higher, and capital allocation visibly active. The market correctly pays up.
• Asset-rich, return-poor PSUs (GSFC, GNFC, RCF): single-digit ROCE/ROE, trading below or near book (0.58–1.47×). Govt-of-Gujarat / Govt-of-India ownership constrains capital action. GSFC is the cheapest-on-book in the group, GNFC is second.
• Special situation (FACT, Paradeep): FACT's headline P/E is meaningless after a debt-equity restructuring; Paradeep is recently listed and recovering.

GSFC's P/B of 0.58× is the lowest in the peer set, which is the strongest argument for the stock. But the ROCE of 6.2% is also among the lowest, which is why the discount exists. The peer gap that matters is GSFC vs Chambal: Chambal earns 4.3× the ROCE for 3.2× the P/B. On a return-adjusted basis, Chambal is actually the better value. GSFC needs operating performance to close the gap, not just multiple expansion.

---

9. What to Watch in the Financials

What the financials confirm, contradict, and the next thing to watch

The financials confirm that GSFC is a low-leverage, asset-rich, dividend-paying PSU with a deeply cyclical operating business and a real $3.21-per-share book that has compounded steadily. They contradict the easy "cheap on P/E and P/B" narrative — because (a) earnings have not turned into cash for two years, (b) ROCE is durably single-digit, and (c) the investment book that makes the balance sheet look great is functionally locked up by PSU governance. The stock trades at 0.58× book for valid reasons, not despite them.

What changes the view next? Watch operating cash flow. Two consecutive quarters of CFO above $35M each — meaning the working-capital build reverses — would argue that the FY2024–25 cash drain was a transitory subsidy/inventory issue rather than structural, and would support a re-rating of P/E and P/B toward the peer average. If CFO stays sub-$23M per quarter through FY2026, the equity story is "yield + book-value floor" only, and the multiple stays where it is.

The first financial metric to watch is operating cash flow (CFO) — specifically, whether the next two quarterly statements show CFO returning to $35M+ per quarter on the back of a working-capital release.